Trial Profile
A Randomized, Double-Blind, Placebo Controlled Study to Evaluate Efficacy and Safety of Nefecon in Patients with Primary IgA Nephropathy at Risk of Progressing to End-Stage Renal Disease (NefIgArd)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 12 Apr 2024
Price :
$35
*
At a glance
- Drugs Budesonide (Primary)
- Indications IgA nephropathy
- Focus Registrational; Therapeutic Use
- Acronyms NefIgArd
- Sponsors Calliditas Therapeutics
- 08 Apr 2024 According to a Calliditas Therapeutics media release, data from this study will be presented at the International Society of Nephrology's World Congress of Nephrology.
- 19 Mar 2024 According to an Everest Medicines media release, based on results from this trial the Singapore Health Sciences Authority (HSA) has approved NEFEGAN for the treatment of primary immunoglobulin A nephropathy (IgAN) in adults at risk of disease progression.
- 20 Dec 2023 Results presented in a Calliditas Therapeutics media release.